

References

- Abbas, G., & Krasna, M. (2017). Overview of esophageal cancer. *Annals of Cardiothoracic Surgery*, 6(2), 131–136. <https://doi.org/10.21037/acs.2017.03.03>
- Abuetabh, Y., Wu, H. H., Chai, C., Al Yousef, H., Persad, S., Sergi, C. M., & Leng, R. (2022). DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities. *Experimental & Molecular Medicine*, 54(10), 1658–1669. <https://doi.org/10.1038/s12276-022-00863-4>
- Acharya, R., Mahapatra, A., Verma, H. K., & Bhaskar, L. V. K. S. (2023). Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review. *Current Oncology*, 30(11), 9542–9568. <https://doi.org/10.3390/curroncol30110691>
- Amjad, M. T., Anusha Chidharla, & Kasi, A. (2023, February 27). *Cancer Chemotherapy*. Nih.gov; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK564367/>
- Baladi, A., Tafenzi, H. A., Megzar, F.-Z., Cisse, I. K., Zouiten, O., Afani, L., Essaadi, I., El Fadli, M., & Belbaraka, R. (2025). Locally advanced and metastatic esophageal squamous cell carcinoma in Morocco: from diagnosis to treatment. *Ecancermedicalscience*, 19. <https://doi.org/10.3332/ecancer.2025.1882>
- Basile, K. J., Abel, E. V., & Aplin, A. E. (2011). Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. *Oncogene*, 31(19), 2471–2479. <https://doi.org/10.1038/onc.2011.424>
- Basile, K. J., & Aplin, A. E. (2012). Resistance to Chemotherapy. *Advances in Pharmacology*, 315–334. <https://doi.org/10.1016/b978-0-12-397927-8.00010-5>
- Basu, S., Dong, Y., Kumar, R., Jeter, C., & Tang, D. G. (2022). Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis. *Seminars in Cancer Biology*, 78, 90–103. <https://doi.org/10.1016/j.semcancer.2021.04.021>

- Berry, M. F. (2014a). Esophageal cancer: staging system and guidelines for staging and treatment. *Journal of Thoracic Disease*, 6(Suppl 3), S289. <https://doi.org/10.3978/j.issn.2072-1439.2014.03.11>
- Berry, M. F. (2014b). Esophageal cancer: staging system and guidelines for staging and treatment. *PubMed*, 6 Suppl 3, S289-97. <https://doi.org/10.3978/j.issn.2072-1439.2014.03.11>
- Birkmire, J., Haslam, A., Hernandez, E. F., & Olivier, T. (2025). Why the duration of cancer treatment requires a closer look: An empirical analysis of recent FDA approvals. *European Journal of Cancer*, 228, 115701. <https://doi.org/10.1016/j.ejca.2025.115701>
- Cecati, M., Pozzi, V., Pompei, V., Schiavoni, V., Fumarola, S., Romagnoli, A., Tossetta, G., Montana, A., Polizzi, A., Sartini, D., & Campagna, R. (2026). Cisplatin as a Xenobiotic Agent: Molecular Mechanisms of Actions and Clinical Applications in Oncology. *Journal of Xenobiotics*, 16(1), 9. <https://doi.org/10.3390/jox16010009>
- Chaber-Ciopinska, A., Kiprian, D., Kawecki, A., & Kaminski, M. F. (2016). Surveillance of patients at high-risk of squamous cell esophageal cancer. *Best Practice & Research Clinical Gastroenterology*, 30(6), 893–900. <https://doi.org/10.1016/j.bpg.2016.10.003>
- Chai, T., Shen, Z., Zhang, Z., Chen, S., Gao, L., Zhang, P., Lin, W., Kang, M., & Lin, J. (2020). LGR6 is a potential diagnostic and prognostic marker for esophageal squamous cell carcinoma. *Journal of Clinical Laboratory Analysis*, 34(4). <https://doi.org/10.1002/jcla.23121>
- Chern, Y.-J., & T. Tai, I. (2020). Adaptive response of resistant cancer cells to chemotherapy. *Cancer Biology and Medicine*, 17(4), 842–863. <https://doi.org/10.20892/j.issn.2095-3941.2020.0005>

- Dhanyamraju, P. K. (2024). Drug resistance mechanisms in cancers: Execution of pro-survival strategies. *The Journal of Biomedical Research*, 38(2), 95. <https://doi.org/10.7555/jbr.37.20230248>
- Dickens, E., & Ahmed, S. (2018). Principles of cancer treatment by chemotherapy. *Surgery (Oxford)*, 36(3), 134–138. <https://doi.org/10.1016/j.mpsur.2017.12.002>
- Ehara, T., Uehara, T., Yoshizawa, T., Kinugawa, Y., Kobayashi, S., Iwaya, M., Nagaya, T., Miyagawa, Y., & Soejima, Y. (2021). *High Expression of LGR6 is A Poor Prognostic Factor In Esophageal Carcinoma*. <https://doi.org/10.21203/rs.3.rs-1087394/v1>
- Eltorky, H., AbdelMageed, M., Ismail, H., Zahran, F., Guirgis, A., Olsson, L., Lindmark, G., Hammarström, M.-L., Hammarström, S., & Sitohy, B. (2024). LGR6 is a prognostic biomarker for less differentiated tumors in lymph nodes of colon cancer patients. *Frontiers in Oncology*, 14. <https://doi.org/10.3389/fonc.2024.1393075>
- Feng, Q., Li, S., Ma, H.-M., Yang, W.-T., & Zheng, P.-S. (2021). LGR6 activates the Wnt/ β -catenin signaling pathway and forms a β -catenin/TCF7L2/LGR6 feedback loop in LGR6^{high} cervical cancer stem cells. *Oncogene*, 40(42), 6103–6114. <https://doi.org/10.1038/s41388-021-02002-1>
- Focaccetti, C., Bruno, A., Magnani, E., Bartolini, D., Principi, E., Dallaglio, K., Bucci, E. O., Finzi, G., Sessa, F., Noonan, D. M., & Albini, A. (2015). Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes. *PLOS ONE*, 10(2), e0115686. <https://doi.org/10.1371/journal.pone.0115686>
- Fodale, V., Pierobon, M., Liotta, L., & Petricoin, E. (2011). Mechanism of Cell Adaptation. *The Cancer Journal*, 17(2), 89–95. <https://doi.org/10.1097/ppo.0b013e318212dd3d>

- Garg, P., Salgia, R., & Singhal, S. S. (2026). Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure. *Journal of Ovarian Research*, 19(1). <https://doi.org/10.1186/s13048-026-02115-9>
- Grommisch, D., Wang, M., Eenjes, E., Svetličič, M., Deng, Q., Giselsson, P., & Genander, M. (2024). Defining the contribution of Troy-positive progenitor cells to the mouse esophageal epithelium. *Developmental Cell*, 59(10), 1269-1283.e6. <https://doi.org/10.1016/j.devcel.2024.03.011>
- Hagan, C. E., Sheehan, V. M., Rezanka, C. M., Li, M. A., Martínez-Escardó, L., Campbell, K. J., Snyder, A. G., Headley, M., & Oberst, A. (2025). Apoptotic cells promote circulating tumor cell survival and metastasis. *Communications Biology*, 8(1). <https://doi.org/10.1038/s42003-025-08541-7>
- He, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024). Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies. *Signal Transduction and Targeted Therapy*, 9(1). <https://doi.org/10.1038/s41392-024-01891-4>
- Hegde, G. V., de la Cruz, C., Eastham-Anderson, J., Zheng, Y., Sweet-Cordero, E. A., & Jackson, E. L. (2012). Residual Tumor Cells That Drive Disease Relapse after Chemotherapy Do Not Have Enhanced Tumor Initiating Capacity. *PLoS ONE*, 7(10), e45647. <https://doi.org/10.1371/journal.pone.0045647>
- Hu, J. L., Todhunter, M. E., LaBarge, M. A., & Gartner, Z. J. (2017). Opportunities for organoids as new models of aging. *Journal of Cell Biology*, 217(1), 39–50. <https://doi.org/10.1083/jcb.201709054>
- Huang, H., Yu, K., Mohammadi, A., Efstathios Karathanasis, Godley, A., & Yu, J. S. (2017). It's Getting Hot in Here: Targeting Cancer Stem-like Cells with Hyperthermia.

- Journal of Stem Cell and Transplantation Biology*, 2(2), 113.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6287629/>
- Koren, E., Yosefzon, Y., Ankawa, R., Soteriou, D., Jacob, A., Nevelsky, A., Ben-Yosef, R., Bar-Sela, G., & Fuchs, Y. (2018). ARTS mediates apoptosis and regeneration of the intestinal stem cell niche. *Nature Communications*, 9(1).
<https://doi.org/10.1038/s41467-018-06941-4>
- Kostic, L., Leung, C., Ahmad Murad, K., Kancheva, S., Perna, S., Lee, B., & Barker, N. (2024). Lgr5 marks stem/progenitor cells contributing to epithelial and muscle development in the mouse esophagus. *Nature Communications*, 15(1).
<https://doi.org/10.1038/s41467-024-51559-4>
- Labi, V., & Erlacher, M. (2015). How cell death shapes cancer. *Cell Death & Disease*, 6(3), e1675–e1675. <https://doi.org/10.1038/cddis.2015.20>
- Li, H., Guan, X., Wang, Y., & Guo, H. (2026). Lgr6⁺ cells in the biological system during homeostasis and injury. *Genes & Diseases*, 13(4), 101863.
<https://doi.org/10.1016/j.gendis.2025.101863>
- Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., & Wang, L. (2025). Drug resistance in cancer: molecular mechanisms and emerging treatment strategies. *Molecular Biomedicine*, 6(1).
<https://doi.org/10.1186/s43556-025-00352-w>
- Liao, W., Matsuda, S., Takimoto, T., Fukuda, K., Takeuchi, M., Kawakubo, H., Saya, H., & Kitagawa, Y. (2025). DCF-resistant ESCC redevelops drug sensitivity when combined with calcium channel blockers due to ER stress response. *Esophagus*.
<https://doi.org/10.1007/s10388-025-01146-3>

- Liu, S., Jiang, A., Tang, F., Duan, M., & Li, B. (2025). Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment. *Molecular Cancer*, 24(1). <https://doi.org/10.1186/s12943-025-02323-9>
- Lohan-Codeço, M., Barambo-Wagner, M. L., Nasciutti, L. E., Felipe, L., Meireles, N., & Palumbo, A. (2022). Molecular mechanisms associated with chemoresistance in esophageal cancer. *Cellular and Molecular Life Sciences*, 79(2). <https://doi.org/10.1007/s00018-022-04131-6>
- Maleki, E. H., Bahrami, A. R., & Matin, M. M. (2024). Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance. *Genes & Diseases*, 11(1), 189–204. <https://doi.org/10.1016/j.gendis.2022.11.025>
- Martinho, N., Santos, T. C. B., Florindo, H. F., & Silva, L. C. (2019). Cisplatin-Membrane Interactions and Their Influence on Platinum Complexes Activity and Toxicity. *Frontiers in Physiology*, 9. <https://doi.org/10.3389/fphys.2018.01898>
- Marzagalli, M., Fontana, F., Raimondi, M., & Limonta, P. (2021). Cancer Stem Cells—Key Players in Tumor Relapse. *Cancers*, 13(3), 376. <https://doi.org/10.3390/cancers13030376>
- Mascaux, C., Angelova, M., Vasaturo, A., Beane, J., Hijazi, K., Anthoine, G., Buttard, B., Rothe, F., Willard-Gallo, K., Haller, A., Ninane, V., Burny, A., Sculier, J.-P., Spira, A., & Galon, J. (2019). Immune evasion before tumour invasion in early lung squamous carcinogenesis. *Nature*, 571(7766), 570–575. <https://doi.org/10.1038/s41586-019-1330-0>
- Mercadante, A. A., & Kasi, A. (2023, August 14). *Genetics, Cancer Cell Cycle Phases*. Nih.gov; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK563158/>

- Moore, N., Houghton, J., & Lyle, S. (2011). Slow-Cycling Therapy-Resistant Cancer Cells. *Stem Cells and Development*, 21(10), 1822–1830. <https://doi.org/10.1089/scd.2011.0477>
- Morgan, E., Soerjomataram, I., Rungay, H., Coleman, H. G., Thrift, A. P., Vignat, J., Laversanne, M., Ferlay, J., & Arnold, M. (2022). The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. *Gastroenterology*, 163(3), 649-658.e2. <https://doi.org/10.1053/j.gastro.2022.05.054>
- Olander, A., & Sikandar, S. S. (2026). Branching out: the diverse roles of stem and progenitor cells in mammary gland development. *Journal of Mammary Gland Biology and Neoplasia*, 31(1). <https://doi.org/10.1007/s10911-026-09595-x>
- Parrino, J., Hotchkiss, R. S., & Bray, M. (2007). Immune Cell Apoptosis Prevention as Potential Therapy for Severe Infections. *Emerging Infectious Diseases*, 13(2), 191–198. <https://doi.org/10.3201/eid1302.060963>
- Prakash, R., & Telleria, C. M. (2023). Cancer cell repopulation after therapy: which is the mechanism? *Oncoscience*, 10, 14–19. <https://doi.org/10.18632/oncoscience.577>
- Puhr, H. C., Prager, G. W., & Ilhan-Mutlu, A. (2023). How we treat esophageal squamous cell carcinoma. *ESMO Open*, 8(1), 100789. <https://doi.org/10.1016/j.esmoop.2023.100789>
- Punzi, S., Cittaro, D., Gatti, G., Crupi, G., Botrugno, O. A., Cartalemi, A. A., Gutfreund, A., Oneto, C., Giansanti, V., Battistini, C., Santacatterina, G., Patruno, L., Villanti, I., Palumbo, M., Lavery, D. J., Giannese, F., Graudenzi, A., Caravagna, G., Antoniotti, M., & Nagel, Z. (2025). Early tolerance and late persistence as alternative drug responses in cancer. *Nature Communications*, 16(1). <https://doi.org/10.1038/s41467-024-54728-7>

- Recent advances in early esophageal cancer: diagnosis and treatment based on endoscopy. (2021). *Postgraduate Medicine*. <https://doi.org/10.1080//00325481.2021.1934495>
- Ren, W., Lewandowski, B. C., Watson, J., Aihara, E., Iwatsuki, K., Bachmanov, A. A., Margolskee, R. F., & Jiang, P. (2014). Single Lgr5- or Lgr6-expressing taste stem/progenitor cells generate taste bud cells ex vivo. *Proceedings of the National Academy of Sciences*, *111*(46), 16401–16406. <https://doi.org/10.1073/pnas.1409064111>
- Santos-de-Frutos, K., & Djouder, N. (2021). When dormancy fuels tumour relapse. *Communications Biology*, *4*(1). <https://doi.org/10.1038/s42003-021-02257-0>
- Schiliro, C., & Firestein, B. L. (2021). Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. *Cells*, *10*(5), 1056. <https://doi.org/10.3390/cells10051056>
- Soragni, A., Knudsen, E. S., O'Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., Goodrich, D. W., Jiang, D., Gammon, S. T., Willey, C. D., Boutros, P. C., Sandulache, V. C., Osman, A. A., Myers, J. N., Mehla, K., & Singh, P. K. (2025). Acquired resistance in cancer: towards targeted therapeutic strategies. *Nature Reviews Cancer*, *25*(8), 613–633. <https://doi.org/10.1038/s41568-025-00824-9>
- Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021a). The Influence of Cell Cycle Regulation on Chemotherapy. *International Journal of Molecular Sciences*, *22*(13), 6923. <https://doi.org/10.3390/ijms22136923>
- Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021b). The Influence of Cell Cycle Regulation on Chemotherapy. *International Journal of Molecular Sciences*, *22*(13), 6923. <https://doi.org/10.3390/ijms22136923>

- Sunaga, N., Kaira, K., Shimizu, K., Tanaka, I., Miura, Y., Nakazawa, S., Ohtaki, Y., Kawabata-Iwakawa, R., Sato, M., Girard, L., Minna, J. D., & Hisada, T. (2023). The oncogenic role of LGR6 overexpression induced by aberrant Wnt/ β -catenin signaling in lung cancer. *Thoracic Cancer*, 15(2), 131–141. <https://doi.org/10.1111/1759-7714.15169>
- Sunaga, N., Kaira, K., Shimizu, K., Tanaka, I., Miura, Y., Nakazawa, S., Yoichi Ohtaki, Reika Kawabata-Iwakawa, Sato, M., Girard, L., Minna, J. D., & Takeshi Hisada. (2023). The oncogenic role of LGR6 overexpression induced by aberrant Wnt/ β -catenin signaling in lung cancer. *Thoracic Cancer*, 15(2), 131–141. <https://doi.org/10.1111/1759-7714.15169>
- Tan, E. W., Singh, S. K., Dua, K., Gupta, G., Lee, W. L., Wong, R. S. Y., Tan, K. O., & Goh, B. H. (2025). Cancer stem cells: mitochondria signalling pathway and strategies for therapeutic interventions. *Molecular Biology Reports*, 52(1). <https://doi.org/10.1007/s11033-025-10748-0>
- Torti, D., & Trusolino, L. (2011). Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. *EMBO Molecular Medicine*, 3(11), 623–636. <https://doi.org/10.1002/emmm.201100176>
- Watanabe, M., Baba, Y., Yoshida, N., Ishimoto, T., Nagai, Y., Iwatsuki, M., Iwagami, S., & Baba, H. (2014). Outcomes of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Esophagectomy in Patients with Resectable Node-Positive Esophageal Cancer. *Annals of Surgical Oncology*, 21(9), 2838–2844. <https://doi.org/10.1245/s10434-014-3684-8>
- Weidenbaum, C., & Gibson, M. K. (2022). Approach to Localized Squamous Cell Cancer of the Esophagus. *Current Treatment Options in Oncology*, 23(10), 1370–1387. <https://doi.org/10.1007/s11864-022-01003-w>

- Yusupova, M., Ankawa, R., Yosefzon, Y., Meiri, D., Bachelet, I., & Fuchs, Y. (2023). Apoptotic dysregulation mediates stem cell competition and tissue regeneration. *Nature Communications*, *14*(1). <https://doi.org/10.1038/s41467-023-41684-x>
- Zhan, T., N Rindtorff, & Boutros, M. (2016). Wnt signaling in cancer. *Oncogene*, *36*(11), 1461–1473. <https://doi.org/10.1038/onc.2016.304>
- Zio, D. D., Cianfanelli, V., & Cecconi, F. (2013). New Insights into the Link Between DNA Damage and Apoptosis. *Antioxidants & Redox Signaling*, *19*(6), 559–571. <https://doi.org/10.1089/ars.2012.4938>